Psychiatry and Neurology, Neurology · Seattle, WA
NPI
1457360836
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
550 17th Ave Ste 540
Seattle, WA, 98122
Phone (206) 386-3880
Groups this clinician bills Medicare through
Medicare paid, 2024
$266K
26,532 services
Medicare patients, 2024
455
Average age 75
Drug cost, 2024
$2.3M
4,727 prescriptions
Company payments, 2025
$8,790
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pravin Khemani was code J0585 (injection, onabotulinumtoxina, 1 unit), 11,400 times for 25 patients. In total Pravin Khemani billed 26,532 services in 26 codes, and Medicare paid $266K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-06-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 11,400 | 25 | $4.99 | $57K |
| J0586 Injection, abobotulinumtoxina, 5 units | Office | 9,220 | 32 | $6.86 | $63K |
| 99214 Office E&M - Established | Office | 343 | 270 | $97.92 | $34K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 298 | 212 | $13.60 | $4,052 |
| 99215 Office E&M - Established | Office | 254 | 195 | $147.37 | $37K |
| 95874 Musculoskeletal | Office | 129 | 55 | $70.59 | $9,106 |
| 64616 Musculoskeletal | Office | 124 | 52 | $161.52 | $20K |
| 99205 Office E&M - New | Office | 49 | 49 | $153.98 | $7,545 |
| 99213 Office E&M - Established | Office | 40 | 38 | $66.48 | $2,659 |
| 64612 Musculoskeletal | Office | 32 | 15 | $168.58 | $5,395 |
| 99204 Office E&M - New | Office | 18 | 18 | $115.41 | $2,077 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 16 | 15 | $22.59 | $361 |
By year: 2022 $211K for 20,138 services; 2023 $234K for 24,087 services; 2024 $266K for 26,532 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pravin Khemani prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 1,028 prescriptions and refills. In total Pravin Khemani wrote 4,727 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 1,028 | 2,129 | 261 | $37K |
| Rytary Carbidopa/Levodopa | 517 | 907 | 108 | $948K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 329 | 694 | 86 | $18K |
| Rasagiline Mesylate Generic | 267 | 584 | 75 | $48K |
| Clonazepam Generic | 225 | 351 | 61 | $7,170 |
| Amantadine Amantadine Hcl | 214 | 381 | 53 | $14K |
| Primidone Generic | 157 | 347 | 45 | $5,803 |
| Propranolol Hcl Generic | 120 | 232 | 38 | $2,695 |
| Gabapentin Generic | 114 | 246 | 45 | $2,902 |
| Rivastigmine Rivastigmine Tartrate | 83 | 187 | 31 | $9,826 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 79 | 182 | 22 | $1,746 |
| Duloxetine Hcl Generic | 77 | 187 | 21 | $1,492 |
| Memantine Hcl Generic | 76 | 148 | 17 | $2,145 |
| Zonisamide Generic | 71 | 117 | 17 | $2,779 |
| Propranolol Hcl Er Propranolol Hcl | 67 | 185 | 22 | $3,713 |
Brand drugs: 1,054 claims; generic drugs: 3,673 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pravin Khemani $8,790 ($8,790 in general payments such as food, travel and fees) from 9 companies. The largest payer was Cala Health, Inc. with $5,563.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.